# US 2026/0226561 A1 · A method for sorting colorectal cancer and advanced adenoma and use of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0226561 A1
- Document ID: US20260226561A1
- Status: Published application
- Kind: A1
- Application number: 19/572,000
- Filed: 2026-03-19
- Published: 2026-08-06
- Earliest claimed: 2021-12-31
- Assignees: INOGENIX Inc.
- Applicants: INOGENIX Inc.
- Inventors: Da som HWANG; Hyo seok Yang
- Web page: https://patentgrep.com/patent/US20260226561A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/68: involving nucleic acids
- C12Q 1/6851: Quantitative amplification
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a detecting method for colorectal cancer and advanced adenoma group, comprising measuring the relative expression level of MKi67, KRT19, EpCAM, TYMS, PPARG, MCAM, ANKHD1-EIF4EBP3, SNAI2, MMP23B, FOXA2, NPTN, GPR15, TERT, VIM, and ERBB2 genes or proteins encoded by the genes in sample, wherein if the MKi67, KRT19 and EpCAM genes are expressed higher than other genes, it is judged as a normal group, if the TYMS, PPARG, MCAM, and ANKHD1-EIF4EBP3 genes are expressed higher than other genes, it is judged as a colorectal cancer group, if the SNAI2, MMP23B, and FOXA2 genes are expressed higher than other genes, it is judged as an advanced adenoma group or colorectal cancer group, if the NPTN, GPR15, TERT, VIM and ERBB2 genes are expressed higher than other genes, it is judged as an advanced adenoma group.

## Claims

### Claim 1

A method for increasing the likelihood of making a positive colorectal cancer diagnosis, comprising:
a) separating a total RNA from cells obtained from a specimen;
b) synthesizing cDNA from a separated total RNA;
c) performing a quantitative polymerase chain reaction (qPCR) for the synthesized cDNA by using a primer set and a fluorescence-labeled probe capable of amplifying and detecting MKi67, KRT19, and EpCAM genes; a primer set and a fluorescence-labeled probe capable of amplifying and detecting TYMS, PPARG, MCAM and ANKHD1-EIF4EBP3 genes; and a primer set and a fluorescence-labeled probe capable of amplifying and detecting glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a control gene;
d) measuring fluorescence during the qPCR process; and
e) obtaining a relative expression level by measuring the fluorescence,
wherein the relative expression level is expressed as 2−ΔCq, and 2−ΔCq can be calculated using the following equation:
2
-
Δ
⁢
Cq
=
2
-
(
target
⁢
gene
⁢
Cq
-
GAPDH
⁢
gene
⁢
Cq
)
[
Calculation
⁢
formula
]
wherein the target genes are MKi67, KRT19, EpCAM, TYMS, PPARG, MCAM, ANKHD1-EIF4EBP3 and the Cq value represents the cycle number at which a certain fluorescence value is set as a threshold and this threshold is reached,
wherein the expression level of TYMS, PPARG, MCAM, and ANKHD1-EIF4EBP3 genes in the specimen that is higher than the expression level of the MKi67, KRT19 and EpCAM genes in the specimen increases the likelihood that a specimen also having a detected expression level of TYMS, PPARG, MCAM, and ANKHD1-EIF4EBP3 genes is indicative of a positive colorectal cancer diagnosis.
